Deerfield Management Company, L.P. (Series C) Bellus Health Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $4.11 Million - $5.38 Million	500,000 Added 16.23%	3,581,000 $29.4 Million
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $5.44 Million - $7.3 Million	608,000 Added 24.59%	3,081,000 $32.5 Million
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $7.75 Million - $12 Million	-1,199,808 Reduced 32.67%	2,473,000 $22.9 Million
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $6.8 Million - $9.78 Million	1,223,808 Added 49.97%	3,672,808 $25.3 Million
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $12.9 Million - $20.3 Million	2,449,000 New	2,449,000 $19.7 Million

Others Institutions Holding BLU

# of Institutions

Shares Held

128K

Call Options Held

Put Options Held

Pendal Group LTD

128K
Shares

$0
0.01% of portfolio

View Full List

About BELLUS Health Inc.

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

More about BLU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account